摘要
目的:研究Bmi-1基因能否作为儿童ALL的临床风险分析和预后分析的生物标志物。方法:通过qRTPCR检测127例初诊ALL患儿骨髓标本中Bmi-1基因的表达水平,同时应用Western blot技术检测对应标本中Bmi-1蛋白的表达情况。根据不同的临床风险分级,将收集到的骨髓标本分为高危、中危、低危3组,分析Bmi-1的表达与ALL患儿临床风险分级之间的关系。根据强的松试验敏感性将标本分为敏感和不敏感2组,比较Bmi-1的表达在2组之间是否有差异。根据Bmi-1表达量的中位数,将标本分成高水平和低水平2组,依据Kaplan-Meier方法计算儿童ALL患者预后与Bmi-1表达水平的相关性。结果:低风险组Bmi-1表达水平最低;高风险组Bmi-1表达水平最高,中风险组Bmi-1表达水平介于低风险组和高风险组之间,且统计结果有显著性差异(P <0.05)。强的松试验不敏感组的表达明显高于强的松试验敏感组(P <0.001)。Bmi-1表达水平高的患者无复发存活率明显低于Bmi-1表达水平低的患者,前者为73.0%,后者为90.6%,在统计学方面有显著性差异(P<0.001)。结论:Bmi-1可以作为1种新的儿童ALL临床风险分析指标和预后的分子标志物。
Objective:To study whether the Bmi-1 gene can be a biomarker for analysis of clinical risk stratification and prognosis of ALL patients.Methods:The expression level of Bmi-1 gene in bone marrow samples from 127 cases of newly diagnosed ALL was detected by qRT-PCR,at the same time the expression level of Bmi-1 protein in bone marrow samples from above-mentioned cases was detected by Western blot.The collected samples were divided into 3 groups:high,intermediate and low risk according to clinical risk stratfication,the relationship between Bmi-1 expression and risk grade of ALL patients was analyzed;at the same time the collected samples were divided into 2 groups:prednisone good response(PGR)and prednisone poor respouse(PPR)according to the sensitivity of prednison test,and the sensitivily to prednisone in 2 groups was compared;moreover,the collected samples were divided into 2 groups:high level and low level according to median of Bmi-1 level,and the relation of Bmi-1 level with prognosis of patients was analyzed by using the Kaplan-Meier method.Results:The expression level of Bmi-1 in low risk group was lowest,while that in high risk group was highest,however that in intermediat risk group was between the low and high risk groups,statistical analysis showed significant difference(P<0.05).The expression level of Bmi-1 in PPR group was significantly higher than that in PGR group(P<0.001).The Kaplan-Meier analysis showed that the RFS rate in Bmi-1 high expression group was significantly lower than that in Bmi-1 low expression group(73.0%vs 90.6%)(P<0.001).Conclusion:The Bmi-1 can be used as a molecular marker for the analysis of chinical risk and prognosis of pediatric ALL.
作者
邝彩云
罗霭玲
蔡蔓斯
徐令
张文英
KUANG Cai-Yun;LUO Ai-Ling;CAI Man-Si;XU Ling;ZHANG Wen-Ying(Department of Hematology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,Guangdong Province,China;Institute of Pediatrics,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,Guangdong Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2019年第3期741-746,共6页
Journal of Experimental Hematology
基金
广东省自然科学基金项目(2013B021800030)
关键词
急性淋巴细胞白血病
BMI-1
临床风险分级
强的松试验
预后
acute lymphoblastic leukemia
Bmi-1
clinical risk grading
prednisone response test
prognosis molecular marker
